PMID- 16914137
OWN - NLM
STAT- MEDLINE
DCOM- 20070111
LR  - 20131121
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 546
IP  - 1-3
DP  - 2006 Sep 28
TI  - Inhibition of scratching behavior associated with allergic dermatitis in mice by 
      tacrolimus, but not by dexamethasone.
PG  - 189-96
AB  - Itching is the most important problem in many allergic and inflammatory skin 
      diseases especially in atopic dermatitis. However, animal models for allergic 
      dermatitis useful for the study of itching have rarely been established. We 
      established a mouse allergic dermatitis model involving frequent scratching 
      behavior by repeated painting with 2,4-dinitrofluorobenzene (DNFB) acetone 
      solution onto the mouse skin, and comparatively examined the effects of 
      tacrolimus and dexamethasone on the dermatitis and associated scratching 
      behavior. Repeated DNFB painting caused typical dermatitis accompanied by 
      elevated serum immunoglobulin E (IgE) and frequent scratching behavior. An 
      apparent thickening of the epidermis and dermis, and the significant accumulation 
      of inflammatory cells were observed. Increased interferon (IFN)-gamma mRNA 
      expression and the induction of interleukin (IL)-4 and IL-5 mRNA expression were 
      also observed in the skin lesion. The scratching behavior was inhibited by 
      dibucaine and naloxone. Although tacrolimus reduced the increased expression of 
      IFN-gamma and IL-4 mRNA, dexamethasone potently depressed that of IFN-gamma, IL-4 
      and IL-5 mRNA. Dexamethasone inhibited the accumulation of lymphocytes and 
      eosinophils, although tacrolimus did not. Both drugs failed to inhibit the 
      elevation of serum IgE levels. Tacrolimus significantly inhibited the scratching 
      behavior that was associated with the inhibition of nerve fiber extension into 
      the epidermis, whereas dexamethasone failed to have any effect. The mouse 
      dermatitis model seems to be beneficial for the study of itching associated with 
      allergic dermatitis, such as atopic dermatitis, and tacrolimus seems to exhibit 
      an anti-itch effect through the inhibition of nerve fiber extension at least in 
      part.
FAU - Inagaki, Naoki
AU  - Inagaki N
AD  - Department of Pharmacology, Gifu Pharmaceutical University, 5-6-1 
      Mitahorahigashi, Gifu 502-8585, Japan. inagakin@gifu-pu.ac.jp
FAU - Shiraishi, Noriko
AU  - Shiraishi N
FAU - Igeta, Katsuhiro
AU  - Igeta K
FAU - Itoh, Tomokazu
AU  - Itoh T
FAU - Chikumoto, Takao
AU  - Chikumoto T
FAU - Nagao, Masafumi
AU  - Nagao M
FAU - Kim, John Fan
AU  - Kim JF
FAU - Nagai, Hiroichi
AU  - Nagai H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060725
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Allergens)
RN  - 0 (Anesthetics, Local)
RN  - 0 (Antipruritics)
RN  - 0 (Glucocorticoids)
RN  - 0 (Interleukin-5)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (RNA, Messenger)
RN  - 207137-56-2 (Interleukin-4)
RN  - 36B82AMQ7N (Naloxone)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 82115-62-6 (Interferon-gamma)
RN  - D241E059U6 (Dinitrofluorobenzene)
RN  - L6JW2TJG99 (Dibucaine)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Allergens/immunology
MH  - Anesthetics, Local/pharmacology
MH  - Animals
MH  - Antipruritics/*pharmacology/therapeutic use
MH  - Behavior, Animal/*drug effects
MH  - Dermatitis, Allergic Contact/*drug therapy/immunology/pathology
MH  - Dermatitis, Atopic/*drug therapy/immunology/pathology
MH  - Dexamethasone/pharmacology
MH  - Dibucaine/pharmacology
MH  - Dinitrofluorobenzene/immunology
MH  - Disease Models, Animal
MH  - Glucocorticoids/pharmacology
MH  - Immunoglobulin E/blood
MH  - Interferon-gamma/biosynthesis
MH  - Interleukin-4/biosynthesis
MH  - Interleukin-5/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Naloxone/pharmacology
MH  - Narcotic Antagonists/pharmacology
MH  - Pruritus/*prevention & control
MH  - RNA, Messenger/biosynthesis
MH  - Skin/drug effects/immunology/pathology
MH  - Tacrolimus/*pharmacology/therapeutic use
EDAT- 2006/08/18 09:00
MHDA- 2007/01/12 09:00
CRDT- 2006/08/18 09:00
PHST- 2006/04/17 00:00 [received]
PHST- 2006/07/02 00:00 [revised]
PHST- 2006/07/13 00:00 [accepted]
PHST- 2006/08/18 09:00 [pubmed]
PHST- 2007/01/12 09:00 [medline]
PHST- 2006/08/18 09:00 [entrez]
AID - S0014-2999(06)00760-6 [pii]
AID - 10.1016/j.ejphar.2006.07.019 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2006 Sep 28;546(1-3):189-96. doi: 10.1016/j.ejphar.2006.07.019. 
      Epub 2006 Jul 25.